Department of Oncology, No. 903 Hospital of PLA Joint Logistic Support Force, Xi Hu Affiliated Hospital of Hangzhou Medical College, Hangzhou, China.
Department of Gastroenterology, Hangzhou Xixi Hospital, Hangzhou, China.
Assay Drug Dev Technol. 2023 Jul;21(5):202-211. doi: 10.1089/adt.2022.099. Epub 2023 Jul 10.
Colorectal carcinoma (CRC) is a fatal disease and ranks as the third most prevalent cancer globally. Stemness and drug resistance are the main causes of tumor recurrence in CRC. This study attempted to probe the impact of TWIST1 on CRC stemness and resistance to oxaliplatin and to uncover the underlying regulatory mechanism of TWIST1. mRNA expression data from The Cancer Genome Atlas-CRC were subjected to differential analysis. The target gene in the study was determined according to literature citation. ChIPBase was utilized to predict likely targets downstream of the target gene. Pearson was employed for correlation analysis. Quantitative real-time polymerase chain reaction was used to assess TWIST1 and microfibrillar-associated protein 2 (MFAP2) levels in CRC and normal cells. The cell viability was assayed through cell counting kit-8 and IC value was calculated. Flow cytometry was applied to assay the cell apoptosis. Apoptosis assays were applied to evaluate cell apoptosis. CD44, CD133, SOX-2, ERCC1, GST-π, MRP, and P-gp protein expression levels were assayed by Western blot. The targeting relationship between TWIST1 and MFAP2 was ascertained through dual-luciferase and chromatin immunoprecipitation (ChIP). TWIST1 possessed high expression in CRC tissue and cells. TWIST1 knockdown strikingly promoted cell apoptosis and reduced cell stemness and cell resistance to oxaliplatin. Bioinformatics prediction suggested that MFAP2, which was overexpressed in CRC tissue and cells, was the target gene downstream of TWIST1. Dual-luciferase and ChIP assays validated that there was a targeting relationship between TWIST1 and MFAP2. The results of the rescue assay demonstrated that TWIST1 fostered CRC stemness and oxaliplatin resistance by activating MFAP2 expression. These outcomes implied that TWIST1 enhanced CRC stemness and oxaliplatin resistance by activating the transcription of MFAP2. Therefore, TWIST1/MFAP2 axis possibly indicated a mechanism for regulating tumor progression.
结直肠癌(CRC)是一种致命的疾病,是全球第三大常见癌症。肿瘤干细胞特性和耐药性是 CRC 肿瘤复发的主要原因。本研究试图探讨 TWIST1 对 CRC 干细胞特性和对奥沙利铂耐药性的影响,并揭示 TWIST1 的潜在调节机制。对来自癌症基因组图谱-CRC 的 mRNA 表达数据进行差异分析。根据文献引用确定研究中的靶基因。利用 ChIPBase 预测靶基因下游的可能靶点。采用 Pearson 进行相关性分析。采用定量实时聚合酶链反应(qRT-PCR)检测 CRC 和正常细胞中 TWIST1 和微纤维相关蛋白 2(MFAP2)的水平。通过细胞计数试剂盒-8 测定细胞活力并计算 IC 值。应用流式细胞术检测细胞凋亡。应用凋亡测定评估细胞凋亡。通过 Western blot 检测 CD44、CD133、SOX-2、ERCC1、GST-π、MRP 和 P-gp 蛋白表达水平。通过双荧光素酶和染色质免疫沉淀(ChIP)确定 TWIST1 和 MFAP2 之间的靶向关系。TWIST1 在 CRC 组织和细胞中高表达。TWIST1 敲低显著促进细胞凋亡,降低细胞干细胞特性和细胞对奥沙利铂的耐药性。生物信息学预测表明,MFAP2 在 CRC 组织和细胞中过表达,是 TWIST1 下游的靶基因。双荧光素酶和 ChIP 实验验证了 TWIST1 和 MFAP2 之间存在靶向关系。挽救实验的结果表明,TWIST1 通过激活 MFAP2 表达促进 CRC 干细胞特性和奥沙利铂耐药性。这些结果表明,TWIST1 通过激活 MFAP2 转录增强 CRC 干细胞特性和奥沙利铂耐药性。因此,TWIST1/MFAP2 轴可能表明了调节肿瘤进展的一种机制。